Grainofsand you mentioned this in your excellent rationale of why you invested in SNT .
"Company has worked with Fiona Wood for 5 years on scar treatment. There are no other pharma treatments in development and Fiona Wood saw the full inhibition of L enzymes, and the 30% reduction of collagen in scars, over only a 3-month period, as UNPRECEDENTED!
Let's have a look at the science of SNT-6302 owned and or licensed by SNT.
It's a pan-lox inhibitor as with SNT-5505. The difference is its a topical cream.
11 million burns per year worldwide, obviously with scarring.
https://www.recce.com.au/burn-wound-infections/
This YouTube video describes the role of pathogenesis of scarring and subsequent treatment by SNT-6302.
https://youtu.be/AYy7M932O4M?si=VNkuvVNG5iWvyG7W
"Currently, there are no effective therapeutics to ameliorate scar formation and, consequently, patients with significant injuries often endure repeated and expensive surgical and adjunct interventions to improve the scar".
Looks like there is an agent that reduces scarring and reduces pan-lox activity by 66%, which are associated with reduced collagen cross-linking and content . I can't find another drug that betters that in pre-clinical or post clinical programs.
Is SNT-6302 a novel ( unique) class of compound action ?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)